Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NGUYEN-STEVE D VU

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1427133347
CMS profile
337136
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$12,271.21

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NGUYEN-STEVE D VU

NPI 1427133347 · CMS profile ID 337136

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427133347?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427133347?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427133347?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NGUYEN-STEVE D VU, NPI 1427133347, CMS profile ID 337136, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1427133347?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $12,271.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $18.7306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829501525 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.1306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820322421 CMS
GlaxoSmithKline, LLC. $15.3106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802737379 CMS
GlaxoSmithKline, LLC. $0.3906/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802731121 CMS
Grifols USA, LLC $20.3306/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846761249 CMS
HARMONY BIOSCIENCES LLC $15.1306/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078585 CMS
GlaxoSmithKline, LLC. $17.5206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802673901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.8306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763338268 CMS
Regeneron Healthcare Solutions, Inc. $18.0006/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809633851 CMS
Actelion Pharmaceuticals US, Inc. $20.0306/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223405 CMS
GlaxoSmithKline, LLC. $125.0006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802883257 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.8405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763338270 CMS
Gilead Sciences, Inc. $21.7605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848295127 CMS
Actelion Pharmaceuticals US, Inc. $20.0305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223441 CMS
GlaxoSmithKline, LLC. $15.4305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801598861 CMS
GlaxoSmithKline, LLC. $0.3605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802443083 CMS
Actelion Pharmaceuticals US, Inc. $5.4704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223411 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763338272 CMS
GlaxoSmithKline, LLC. $3,600.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802510207 CMS
Genentech USA, Inc. $20.7204/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835958033 CMS
Actelion Pharmaceuticals US, Inc. $20.0304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223409 CMS
AstraZeneca Pharmaceuticals LP $14.4204/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829493493 CMS
Regeneron Healthcare Solutions, Inc. $17.4004/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809633849 CMS
GlaxoSmithKline, LLC. $125.0004/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802894473 CMS
Novartis Pharmaceuticals Corporation $12.3704/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813343779 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.0004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789180217 CMS
GlaxoSmithKline, LLC. $0.3504/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802735151 CMS
Teva Pharmaceuticals USA, Inc. $18.5203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839607733 CMS
Actelion Pharmaceuticals US, Inc. $28.2903/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223429 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0103/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763338274 CMS
Actelion Pharmaceuticals US, Inc. $30.3303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223427 CMS
Actelion Pharmaceuticals US, Inc. $17.8703/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223439 CMS
GlaxoSmithKline, LLC. $15.5203/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801980481 CMS
GlaxoSmithKline, LLC. $0.9303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802450691 CMS
Sunovion Pharmaceuticals Inc. $6.4303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821918621 CMS
Genentech USA, Inc. $17.9703/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835958031 CMS
AstraZeneca Pharmaceuticals LP $15.2703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829723275 CMS
AstraZeneca Pharmaceuticals LP $0.5003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830016835 CMS
Grifols USA, LLC $17.2703/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846750149 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7702/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763338276 CMS
United Therapeutics Corporation $19.4402/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839124605 CMS
Actelion Pharmaceuticals US, Inc. $26.2802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223437 CMS
Actelion Pharmaceuticals US, Inc. $28.9902/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788223415 CMS
GlaxoSmithKline, LLC. $10.6302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801597077 CMS
GlaxoSmithKline, LLC. $1.1202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802714543 CMS
AstraZeneca Pharmaceuticals LP $16.9902/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829611051 CMS
Electromed, Inc. $22.4702/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849600593 CMS
GENZYME CORPORATION $18.9102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843596179 CMS
Sunovion Pharmaceuticals Inc. $18.5002/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821705043 CMS
GlaxoSmithKline, LLC. $13.8402/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802915455 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,245.56 140
PY2020 $8,770.90 80
PY2021 $12,271.21 106
PY2022 $6,235.36 92
PY2023 $403.81 5
PY2024 $1,592.49 13
PY2025 $114.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $6,235.66 20
PY2021 Principal investigator $23,838.94 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $47.31 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159475
Principal investigator 1 Insmed, Inc. $47.31 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159479
Principal investigator 1 Insmed, Inc. $71.02 07/22/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160207
Principal investigator 1 Insmed, Inc. $71.02 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148365
Principal investigator 1 Insmed, Inc. $117.00 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group PA
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148669
Principal investigator 1 Insmed, Inc. $1,708.20 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148741
Principal investigator 1 Insmed, Inc. $71.02 07/11/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160389
Principal investigator 1 Insmed, Inc. $47.31 05/12/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148667
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148359
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148361
Principal investigator 1 Insmed, Inc. $47.31 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148363
Principal investigator 1 Insmed, Inc. $1,766.70 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908159469
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160201
Principal investigator 1 Insmed, Inc. $47.31 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160211
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160217
Principal investigator 1 Insmed, Inc. $71.02 04/05/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160395
Principal investigator 1 Insmed, Inc. $71.02 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148355
Principal investigator 1 Insmed, Inc. $71.02 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908148357
Principal investigator 1 Insmed, Inc. $47.31 03/04/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160401
Principal investigator 1 Insmed, Inc. $1,649.70 01/10/2022 Non-covered Recipient Entity
Central Florida Pulmonary Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908160197